Table 4.
MiRNA-based biomarkers and therapies in clinical trials. ADT: androgen deprivation therapy; mCRPC: metastatic castration-resistant prostate cancer; Enz: enzalutamide; Abi: abiraterone; CTCL: cutaneous T-cell lymphoma; NSCLC: non-small-cell lung cancer.
| MiRNA | Clinical Trial | Biomarker/Therapy | Status |
|---|---|---|---|
| miR-141, miR-375 | NCT02391051 | Prognostic biomarker for low-risk PCa | Phase II |
| miRNA profiling | NCT01220427 | Diagnostic biomarker for high-grade PCa | Phase II |
| miRNA profiling | NCT02964351 | Biomarker for high-PSA PCa | Recruiting |
| Exosomal miRNA signature | NCT02366494 | Prognostic biomarker for PCa under ADT treatment | Active, not recruiting |
| miRNA panel | NCT02471469 | Prognostic biomarker for mCRPC under Enz | Complete recruiting |
| miRNA profiling | NCT01503229 | Prognostic biomarker for mCRPC under Abi | Phase II |
| miRNA profiling | NCT01120236 | Prognostic biomarker for PCa under ADT/cixutumumab | Phase II |
| MRX34 | NCT01829971 | miR-34a-based therapy for multiple solid tumors | Phase I, terminated |
| MRG-106 | NCT03713320 | miR-155 inhibitor for treating CTCL | Phase II |
| TargomiRs | NCT02369198 | miR-16-based therapy for NSCLC | Phase I |